Health-economic Analysis of Diagnosis and Treatment for Osa

695 An Integrated Health-Economic Analysis of OSA—Pietzsch et al relied on aggregate quality-of-life assessments, as opposed to linking quality of life to relevant outcomes observed in OSA.2-6 In this study, we compare 3 commonly employed diagnostic modalities—full-night polysomnography (FN-PSG), split-night polysomnography (SN-PSG), and unattended portable home monitoring (UPHM)—and the established (gold standard) treatment modality of continuous positive airway pressure (CPAP) for moderate-to-severe OSA (apnea-hypopnea index [AHI] ≥ 15 events/h). All input data for the study were compiled from previously published clinical trials and health-economic evaluations. This study evaluates health-related quality of life (HRQoL) and the impact of treatment on 3 negative health outcomes associated with untreated OSA: strokes, myocardial infarctions, and motor vehicle collisions due to excessive daytime sleepiness.7,8 Cost-effectiveness is assessed through the standard metric of the incremental cost-effectiveness ratio (ICER). Scenario analyses are performed to identify critical parameters that might be directly influenced by patients and physicians, including therapy compliance. To account for the chronic nature of OSA, we investigated 2 time frames: a 10-year time horizon and lifetime.